Angiotensin II Type 1 Receptor Inhibition is Associated with Reduced Tachyarrhythmia-Induced Ventricular Interstitial Fibrosis in a Goat Atrial Fibrillation Model

[1]  S. Hohnloser,et al.  Drug therapy , 2022 .

[2]  Gianni Tognoni,et al.  Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). , 2005, American heart journal.

[3]  Michael J. Wilson,et al.  Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. , 2004, Heart rhythm.

[4]  T. Nakano,et al.  Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure. , 2004, American journal of physiology. Heart and circulatory physiology.

[5]  S. Nattel,et al.  Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. , 2004, Cardiovascular research.

[6]  Holly Yu,et al.  Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. , 2004, Journal of the American College of Cardiology.

[7]  J. K. Donahue,et al.  Pathophysiological findings in a model of persistent atrial fibrillation and severe congestive heart failure. , 2004, Cardiovascular research.

[8]  Wen-Chung Yu,et al.  Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. , 2003, European heart journal.

[9]  S. Nattel,et al.  Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. , 2003, Cardiovascular research.

[10]  K. Arakawa,et al.  Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. , 2003, Journal of the American College of Cardiology.

[11]  Maurits A. Allessie,et al.  Reverse Structural and Gap-Junctional Remodeling After Prolonged Atrial Fibrillation in the Goat , 2003, Circulation.

[12]  Simon Stewart,et al.  A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. , 2002, The American journal of medicine.

[13]  E. Bernal,et al.  Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study , 2002, Circulation.

[14]  S. Nattel,et al.  Dynamic Nature of Atrial Fibrillation Substrate During Development and Reversal of Heart Failure in Dogs , 2002, Circulation.

[15]  S. Nattel.  New ideas about atrial fibrillation 50 years on , 2002, Nature.

[16]  D. Dostal.  Regulation of Cardiac Collagen: Angiotensin and Cross-Talk With Local Growth Factors , 2001, Hypertension.

[17]  A. Goette,et al.  Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. , 2000, Circulation.

[18]  K. Arakawa,et al.  Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. , 2000, Circulation.

[19]  A. Goette,et al.  Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. , 2000, Journal of the American College of Cardiology.

[20]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[21]  J. Nerbonne,et al.  Atrial L-type Ca2+ currents and human atrial fibrillation. , 1999, Circulation research.

[22]  S Nattel,et al.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. , 1999, Circulation.

[23]  I. V. Van Gelder,et al.  Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. , 1999, Cardiovascular research.

[24]  S Nattel,et al.  Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. , 1999, Circulation research.

[25]  S. Huang,et al.  Down-regulation of L-type calcium channel and sarcoplasmic reticular Ca(2+)-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: an insight into the mechanism of atrial electrical remodeling. , 1999, Journal of the American College of Cardiology.

[26]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[27]  D. Webb,et al.  Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. , 1998, Circulation.

[28]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[29]  M. Allessie,et al.  Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. , 1997, Circulation.

[30]  S Nattel,et al.  Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. , 1997, Circulation research.

[31]  H. Crijns,et al.  Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. , 1995, Journal of cardiac failure.

[32]  P. Anversa,et al.  The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy. , 1995, Circulation.

[33]  M. Allessie,et al.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. , 1995, Circulation.

[34]  M. Zile,et al.  Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. , 1991, The American journal of physiology.

[35]  W. Kannel,et al.  Epidemiologic features of chronic atrial fibrillation: the Framingham study. , 1982, The New England journal of medicine.